Abstract

Type 2 idiopathic macular telangiectasia (MacTel-2) is a progressive adult-onset macular disease associated with bilateral perifoveal vascular changes, Muller cell degeneration and increased blood-retinal barrier permeability. The pathophysiological mechanisms of MacTel-2 remain unclear, however it was previously reported that anti-retinal antibodies in MacTel-2 patients are a significant feature of the disease. In this study, we aimed to compare the prevalence of anti-retinal antibodies in patients MacTel-2, healthy controls and patients with other retinal diseases. MacTel-2 patients diagnosed with multimodal imaging were enrolled and their disease severities were graded using spectral-domain optical coherence tomography. For comparison, patients with age-related macular degeneration (AMD), inherited retinal diseases (IRDs) or no retinal disease (healthy controls) were recruited as controls. Blood serum samples were screened for immunoglobulin G anti-retinal antibodies by western blotting, followed by densitometry analysis. Odds ratios (OR) with 95% confidence intervals (CI) were calculated and p < 0.05 considered statistically significant. Overall, anti-retinal antibody-positive cases were older (64 ± 15 vs 53 ± 17 years, p < 0.001) and females were more likely to develop anti-retinal antibodies (OR: 2.41, CI: 1.12–5.18). The frequency of anti-retinal antibody detection in MacTel-2 patients (n = 42, 36%) was not significantly different from healthy controls (n = 52, 25%) or IRD patients (n = 18, 25%) and the majority of MacTel-2 patients had no anti-retinal antibodies. In contrast, the frequency of anti-retinal antibody detection was significantly higher in patients with AMD (n = 15, 73%, p < 0.001). The lack of a greater anti-retinal antibody frequency or specificity in the MacTel-2 cohort suggests that antibody mediated immunological mechanisms may play a less significant role in MacTel-2 disease pathogenesis.

RAS ID

51799

Document Type

Journal Article

Date of Publication

5-1-2022

Volume

218

Funding Information

Australian National Health and Medical Research Council under GNT1116360 (FKC), GNT1188694 (FKC), GNT1054712 (FKC), MRF1142962 (FKC), McCusker Charitable Foundation (FKC), Miocevich Retina Fellowship (RHJ); The Macula Foundation (LAY).

School

School of Science

Grant Number

NHMRC Numbers : GNT1116360, GNT1188694, GNT1054712, MRF1142962

Grant Link

http://purl.org/au-research/grants/nhmrc/GNT1116360 http://purl.org/au-research/grants/nhmrc/1142962

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Publisher

Elsevier

Comments

McLenachan, S., Balaratnasingam, C., Jeffery, R. C. H., Chen, S. C., Zhang, D., Chan, G., ... & Chen, F. K. (2022). Anti-retinal IgG antibodies in patients with early and advanced type 2 macular telangiectasia. Experimental Eye Research, 109024. https://doi.org/10.1016/j.exer.2022.109024

Included in

Eye Diseases Commons

Share

 
COinS
 

Link to publisher version (DOI)

10.1016/j.exer.2022.109024